Robert A Kyle

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
    R A Kyle
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:3-9. 2009
  2. ncbi request reprint A long-term study of prognosis in monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 346:564-9. 2002
  3. doi request reprint Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 27:823-9. 2008
  4. pmc Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia
    Robert A Kyle
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma Leuk 13:184-6. 2013
  5. pmc Progression in smoldering Waldenstrom macroglobulinemia: long-term results
    Robert A Kyle
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4462-6. 2012
  6. doi request reprint Targeted therapy of multiple myeloma
    Robert A Kyle
    Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA
    Hematology 17:S125-8. 2012
  7. ncbi request reprint Monoclonal gammopathies of undetermined significance: a review
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Immunol Rev 194:112-39. 2003
  8. doi request reprint The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 115:2155-64. 2009
  9. ncbi request reprint Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 102:3759-64. 2003
  10. pmc IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 9:17-8. 2009

Detail Information

Publications143 found, 100 shown here

  1. pmc Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
    R A Kyle
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:3-9. 2009
    ..This paper provides the current criteria for diagnosis, staging, risk stratification and response assessment of MM...
  2. ncbi request reprint A long-term study of prognosis in monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 346:564-9. 2002
    ..A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited...
  3. doi request reprint Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 27:823-9. 2008
    ..Historically, patients with AL amyloidosis and overt congestive heart failure have had an ominous prognosis with median survival of approximately 6 months...
  4. pmc Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia
    Robert A Kyle
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma Leuk 13:184-6. 2013
    ..The percentage of lymphoplasmacytic cells in the bone marrow, size of the serum monoclonal (M) spike, and hemoglobin value were significant independent risk factors for progression...
  5. pmc Progression in smoldering Waldenstrom macroglobulinemia: long-term results
    Robert A Kyle
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4462-6. 2012
    ..Patients with SWM should be followed and not treated until symptomatic WM develops. Treatment on a clinical trial for those at greatest risk of progression should be considered...
  6. doi request reprint Targeted therapy of multiple myeloma
    Robert A Kyle
    Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA
    Hematology 17:S125-8. 2012
    ..More than 100 agents are in phase I, II or III clinical trials. The most promising are carfilzomib and pomalidomide...
  7. ncbi request reprint Monoclonal gammopathies of undetermined significance: a review
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Immunol Rev 194:112-39. 2003
    ..MGUS may be associated with many different disorders, including lymphoproliferative diseases, leukemia, connective tissue disorders, dermatologic diseases, and neurologic disorders...
  8. doi request reprint The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 115:2155-64. 2009
    ....
  9. ncbi request reprint Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 102:3759-64. 2003
    ..5 g/dL or less, 26% with 1.5 g/dL, 34% for 2.0 g/dL, and 41% for more than 2.5 g/dL...
  10. pmc IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 9:17-8. 2009
    ..During follow-up, 33 of the 48 patients progressed to symptomatic WM. The median time to progression was 4.6 years. The risk of progression to WM was 6% at 1 year, 39% at 3 years, and 55% at 5 years...
  11. ncbi request reprint Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil
    R A Kyle
    Division of Hematology and Internal Medicine Section of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Br J Haematol 108:737-42. 2000
    ..Patients must be treated for at least 6 months before therapy is abandoned because response is slow. Chlorambucil is an effective agent and should be compared with purine analogues or rituxan (Rituximab) in a prospective study...
  12. ncbi request reprint Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    Robert A Kyle
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 21:1093-113, ix. 2007
    ..This article discusses the recognition, prevalence, natural history, and progression of MGUS. Management of the disease is discussed along with its association with other disorders. Information on smoldering multiple myeloma is included...
  13. ncbi request reprint Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 101:2667-74. 2004
    ..The authors reported on the incidence of multiple myeloma in Olmsted County, Minnesota, between 1991 and 2001 and on trends in multiple myeloma incidence over the last 56 years...
  14. pmc Multiple myeloma
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 111:2962-72. 2008
    ..We also provide an update on current concepts of diagnosis and therapy, with an emphasis on how treatments have emerged from a historical perspective after certain important discoveries and the results of experimental studies...
  15. ncbi request reprint Prevalence of monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 354:1362-9. 2006
    ..We used sensitive laboratory techniques to ascertain the prevalence of MGUS in a large population in a well-defined geographic area...
  16. ncbi request reprint Review of 1027 patients with newly diagnosed multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:21-33. 2003
    ..To determine the clinical and laboratory features of newly diagnosed multiple myeloma...
  17. ncbi request reprint Monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 134:573-89. 2006
    ....
  18. ncbi request reprint Epidemiology of the plasma-cell disorders
    Robert A Kyle
    Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 20:637-64. 2007
    ..Tobacco use, obesity, diet, and alcohol ingestion are all possible causes of MM. Clusters of MM have been noted. Multiple cases of MM have been found in first-degree relatives...
  19. ncbi request reprint Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 139:730-43. 2007
    ..The cumulative probability of progression to active MM or amyloidosis was 51% at 5 years, 66% at 10 years and 73% at 15 years; the median time to progression was 4.8 years...
  20. ncbi request reprint Monoclonal gammopathies of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Rev Clin Exp Hematol 6:225-52. 2002
    ..Monoclonal gammopathy of undetermined significance may be associated with various disorders, including lymphoproliferative diseases, leukemia, von Willebrand disease, connective tissue diseases and neurologic disorders...
  21. doi request reprint Treatment of multiple myeloma: a comprehensive review
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 9:278-88. 2009
    ..The M-protein might lead to renal failure, hyperviscosity syndrome, or through the suppression of uninvolved immunoglobulins, recurrent infections. Anemia and hypercalcemia are common complications...
  22. ncbi request reprint Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 356:2582-90. 2007
    ..Prognostic factors for the progression and outcome of this disease are unclear...
  23. ncbi request reprint Management of patients with multiple myeloma: emphasizing the role of high-dose therapy
    R A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma 2:21-8. 2001
    ..Thalidomide produces an objective response in about one third of patients with refractory disease. It currently is being studied in conjunction with dexamethasone for conventional initial therapy...
  24. ncbi request reprint Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:859-66. 2004
    ..To determine the long-term outcome of patients with monoclonal gammopathy of undetermined significance (MGUS)...
  25. ncbi request reprint Multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    N Engl J Med 351:1860-73. 2004
  26. ncbi request reprint Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 25:578-86. 2011
    ..Patients with both MGUS and SMM must be followed up for their lifetime...
  27. doi request reprint History of multiple myeloma
    Robert A Kyle
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Recent Results Cancer Res 183:3-23. 2011
    ..The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide...
  28. ncbi request reprint Update on the treatment of multiple myeloma
    R A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Oncologist 6:119-24. 2001
    ..Thalidomide produces objective response in approximately 30% of refractory patients. The use of intravenous bisphosphonates is recommended for patients with skeletal lesions. Hypercalcemia and renal failure must be treated promptly...
  29. ncbi request reprint Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Lymphoma 5:257-60. 2005
    ..It was concluded that the patients with IgM MGUS should be followed indefinitely...
  30. ncbi request reprint Five decades of therapy for multiple myeloma: a paradigm for therapeutic models
    R A Kyle
    Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 19:910-2. 2005
  31. ncbi request reprint Monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 6:102-14. 2005
    ..Epidemiologic and statistical methods must be used to evaluate these associations...
  32. doi request reprint Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    R A Kyle
    Division of Hematology, Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1121-7. 2010
    ..Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months...
  33. doi request reprint Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    Robert A Kyle
    Department of Medicine, Laboratory Medicine and Pathology, College of Medicine Mayo Clinic, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 5:62-9. 2010
    ....
  34. ncbi request reprint Monoclonal gammopathies of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 18:689-707. 2005
    ..To confirm the findings, we conducted a population-based study on MGUS in the 11 counties of southeastern Minnesota from 1960 to 1994. The risk of progression to a malignant plasma-cell disorder was 1% per year...
  35. ncbi request reprint Focal and segmental glomerulosclerosis and plasma cell proliferative disorders
    David Dingli
    Division of Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 46:278-82. 2005
    ..FSGS can be caused by a variety of conditions, but it has been reported rarely in association with a plasma cell disorder...
  36. pmc Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients
    John P Bida
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:685-93. 2009
    ..To systematically study the association of monoclonal gammopathy of undetermined significance (MGUS) with all diseases in a population-based cohort of 17,398 patients, all of whom were uniformly tested for the presence or absence of MGUS...
  37. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  38. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
    ....
  39. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
    ..To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma...
  40. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  41. pmc Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
    Kristen Detweiler-Short
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:737-40. 2010
    ..Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM...
  42. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
    ..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma...
  43. doi request reprint Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis
    Taxiarchis V Kourelis
    All authors Mayo Clinic, Rochester, MN
    J Clin Oncol 31:4319-24. 2013
    ..The aim of this study was to examine the spectrum of immunoglobulin AL amyloidosis with and without MM, with a goal of defining the optimal bone marrow plasma cell (BMPC) number to qualify as AL amyloidosis with MM...
  44. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  45. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  46. ncbi request reprint Prognostic value of angiogenesis in solitary bone plasmacytoma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1715-7. 2003
    ..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma...
  47. pmc Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition
    Terry M Therneau
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
    Mayo Clin Proc 87:1071-9. 2012
    ..To determine the incidence of monoclonal gammopathy of undetermined significance (MGUS) in the general population and to estimate the duration of occult MGUS before first diagnosis...
  48. doi request reprint Trends and outcomes of modern staging of solitary plasmacytoma of bone
    Rahma Warsame
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:647-51. 2012
    ..The use of modern testing is imperative to characterize a patient's risk for progression. PET/CT plays an important role in the diagnostic work-up...
  49. ncbi request reprint Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 103:3960-3. 2004
    ..Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL...
  50. ncbi request reprint Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:5668-74. 2005
    ..Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression...
  51. pmc Morbidity and mortality among older individuals with undiagnosed celiac disease
    Jonathan D Godfrey
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 139:763-9. 2010
    ..Outcomes of undiagnosed celiac disease (CD) are unclear. We evaluated the morbidity and mortality of undiagnosed CD in a population-based sample of individuals 50 years of age and older...
  52. doi request reprint Serum uric acid: novel prognostic factor in primary systemic amyloidosis
    Shaji Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:297-303. 2008
    ..To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL)...
  53. pmc Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Minnesota, USA
    Am J Hematol 86:251-5. 2011
    ..It also highlights the importance of achieving at least a 90% reduction in the FLC-diff to improve the outcome of patients with light-chain AL...
  54. ncbi request reprint Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:34-9. 2003
    ..To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma...
  55. doi request reprint Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies
    Samih H Nasr
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 59:786-94. 2012
    ..Renal involvement is common in multiple myeloma. In this study, we examined kidney biopsy findings in patients with multiple myeloma and correlated them with their clinical renal and hematologic characteristics...
  56. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  57. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  58. pmc Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:2276-9. 2005
    ..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival...
  59. ncbi request reprint Genomic abnormalities in monoclonal gammopathy of undetermined significance
    Rafael Fonseca
    Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:1417-24. 2002
    ..Similar translocations are found in both MGUS and MM, including t(4;14)(p16.3;q32) and t(14;16)(q32;q23). Moreover, Delta 13 is common in MGUS and unlikely to play a predominant role in the evolution of MGUS to MM...
  60. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
    ..This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial...
  61. pmc Immunoglobulin free light chains and solitary plasmacytoma of bone
    David Dingli
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 108:1979-83. 2006
    ..5 g/dL) or higher (high risk, n = 18). The corresponding progression rates at 5 years were significantly different in the low, intermediate, and high groups: 13%, 26%, and 62%, respectively (P < .001)...
  62. pmc Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 111:785-9. 2008
    ..The serum immunoglobulin FLC ratio is an important additional determinant of clinical outcome in patients with SMM...
  63. ncbi request reprint Bone marrow angiogenesis in multiple myeloma: effect of therapy
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:665-71. 2002
    ..We conclude that the degree of bone marrow angiogenesis is a prognostic marker in patients with multiple myeloma and does not decrease significantly after therapy...
  64. ncbi request reprint Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:3751-7. 2004
    ..Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prognostic marker. We sought to develop a staging system for patients with AL...
  65. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  66. pmc Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma
    Shirshendu Sinha
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 148:853-8. 2010
    ..Among this cohort of patients with myeloma, failure to respond to single agent steroid did not have an adverse impact on eventual outcome...
  67. pmc Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome
    Trista Stankowski-Drengler
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:431-4. 2010
    ..In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders...
  68. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  69. pmc Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
    Shaji Kumar
    Division of Hematology and Internal Medicine, Department of Laboratory Medicine and Pathology, Department of Biochemistry, Mayo Clinic, Rochester, MN, USA
    Blood 116:5126-9. 2010
    ..9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL...
  70. pmc The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
    Cheng E Chee
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:2617-8. 2009
    ..2 years vs 2.3 years, respectively; P = .01)...
  71. pmc Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
    Angela Dispenzieri
    Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 375:1721-8. 2010
    ..The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS...
  72. ncbi request reprint Treatment of multiple myeloma: an emphasis on new developments
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Med 38:111-5. 2006
    ..Patients with relapsed or refractory disease may be treated with dexamethasone, thalidomide and dexamethasone, bortezomib (Velcade, PS-341), or lenalidomide (Revlimid, not yet approved by the Food and Drug Administration)...
  73. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  74. ncbi request reprint Clinical and biologic implications of recurrent genomic aberrations in myeloma
    Rafael Fonseca
    Mayo Cinic Division of Hematology, Department of Laboratory Medicine, Rochester, MN 55905, USA
    Blood 101:4569-75. 2003
    ..More importantly it provides further compelling evidence that MM is composed of subgroups of patients categorized according to their underlying genomic aberrations...
  75. ncbi request reprint International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    ..There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification...
  76. ncbi request reprint Myeloma and the newly diagnosed patient: a focus on treatment and management
    S Vincent Rajkumar
    Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA
    Semin Oncol 29:5-10. 2002
    ..The role of supportive care strategies for patients with bone disease, such as the use of bisphosphonates, is also discussed...
  77. ncbi request reprint Natural history and therapy of 66 patients with mixed cryoglobulinemia
    Alan H Bryce
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 81:511-8. 2006
    ..Treatment is generally directed at the underlying condition. Not all patients require treatment, and many can be followed and treated symptomatically...
  78. doi request reprint Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  79. ncbi request reprint Fracture risk in monoclonal gammopathy of undetermined significance
    L Joseph Melton
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Bone Miner Res 19:25-30. 2004
    ..There was a 2.7-fold increase in the risk of axial fractures but no increase in limb fractures. The pathophysiologic basis for the increased axial fractures should be determined...
  80. ncbi request reprint Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    Cynthia X Ma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:40-2. 2004
    ..In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process...
  81. ncbi request reprint Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Robert A Kyle
    Mayo Clinic, Rochester, MN, USA
    Semin Oncol 30:116-20. 2003
    ..However, the panel felt that current data are inadequate to support the use of any prognostic marker to select the timing and type of therapy, and called for studies on the application of prognostic markers in WM...
  82. ncbi request reprint The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review
    Theresa Hahn
    Roswell Park Cancer Institute, Department of Medicine, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 9:4-37. 2003
    ..The priority area of needed future research is maintenance therapy posttransplantation with nothing versus interferon alpha versus other agents such as corticosteroids or thalidomide or its derivatives...
  83. ncbi request reprint Fracture risk with multiple myeloma: a population-based study
    L Joseph Melton
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Bone Miner Res 20:487-93. 2005
    ..Pathologic fractures, especially of the axial skeleton, are extremely common in patients with multiple myeloma and cluster around the time of diagnosis. Osteoporotic fractures seem to be less of a problem in these patients...
  84. ncbi request reprint Amyloidosis with IgM monoclonal gammopathies
    Morie A Gertz
    Dysproteinemia Clinic and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 30:325-8. 2003
    ..We conclude that the presence of amyloid cardiomyopathy and an increased creatinine concentration had the greatest impact on survival...
  85. pmc Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant
    P N Hari
    Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Leukemia 23:1528-34. 2009
    ..However, neither system was strongly predictive of outcomes, indicating the need for newer schemes incorporating other prognostic markers...
  86. ncbi request reprint Neurological aspects of multiple myeloma and related disorders
    Angela Dispenzieri
    Mayo Clinic, Medicine, Rochester, Minnesota MN 55905, USA
    Best Pract Res Clin Haematol 18:673-88. 2005
    ..The authors will review the neurologic complications of MM, monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia (WM), POEMS syndrome, amyloidosis, and cryoglobulinemia...
  87. ncbi request reprint Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 127:308-10. 2004
    ..The presence of an abnormal kappa/lambda FLC ratio in the serum was associated with a higher risk of MGUS progression (relative risk 2.5; 95% confidence interval: 1.6-4.0; P < 0.001)...
  88. ncbi request reprint Helicobacter pylori infection and monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Divisions of Hematology, Gastroenterology and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:706-8. 2002
    ..pylori infection (33%) by serology, breath or stool testing between patients with MGUS and those with negative monoclonal protein studies. There was no evidence of resolution of MGUS with H. pylori therapy...
  89. pmc Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
    Celine M Vachon
    Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:785-90. 2009
    ..0; 95% CI, 1.4 to 2.8) and MGUS probands (RR, 3.3; 95% CI, 2.1 to 4.8). The increased risk of MGUS in first-degree relatives of MGUS or MM patients implies shared environment and/or genetics...
  90. pmc High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa
    Francis Buadi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 86:554-8. 2011
    ..Future studies are needed to uncover genetic and environmental underpinnings of our finding, and to define the relationship between hypergamma-globulinemia, monoclonal gammopathy of undetermined significance (MGUS), and multiple myeloma...
  91. ncbi request reprint Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  92. doi request reprint Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains
    N Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55905, USA
    Kidney Int 73:1282-8. 2008
    ..We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease...
  93. ncbi request reprint Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis
    S R Hayman
    Departments of Hematology and Internal Medicine and of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 98:2266-8. 2001
    ..2%) of those had translocation (11;14)(q13;q32) for an overall prevalence of the abnormality of 55%. IgH translocations are common in AL, especially the t(11;14)(q13;q32)...
  94. ncbi request reprint High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
    S Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:161-7. 2004
    ..65). The lack of response to initial induction therapy does not appear to preclude a good response to SCT. We recommend that patients with primary refractory MM be offered early SCT...
  95. pmc Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
    S Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1498-505. 2010
    ..A system including both these risk factors allows better prediction of outcome...
  96. ncbi request reprint Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:235-9. 2004
    ..007. BM MVD at the time of initial diagnosis is an important prognostic factor for OS and PFS in patients undergoing autologous transplantation as frontline therapy for myeloma...
  97. ncbi request reprint Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival
    A Dispenzieri
    Division of Hematology and Internal Medicine, and Section of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 19:3350-6. 2001
    ..This article addresses the extent to which eligibility to undergo HSCT is a favorable prognostic feature and explores prognostic factors within the subset of eligible patients...
  98. ncbi request reprint A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
    A K Stewart
    Department of Medicine, Division of Hematology Oncology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Leukemia 21:529-34. 2007
    ..Conversely, the 75% of patients remaining have more favorable outcomes using existing - albeit non-curative - therapeutic options...
  99. ncbi request reprint Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients
    N E Kay
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 98:23-8. 2001
    ..Therapeutic efforts to maintain an intact immune system may be crucial in maximizing chemotherapeutic and/or immunotherapy efforts in this disease...
  100. ncbi request reprint Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation
    S V Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 68:269-75. 2001
    ..It is also prognostic for poor survival and PFS following SCT for myeloma. We recommend that all three methods of estimating BMPC% be routinely performed and that the highest value be used for prognostic purposes...
  101. ncbi request reprint A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death
    D P Steensma
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 97:2522-3. 2001
    ..0001). These findings suggest that a high PCLI in patients with apparently stable, plateau phase MM is an adverse parameter that may predict a short time to disease progression and death...